Increased epoxyeicosatrienoic acids may be part of a protective mechanism in human ulcerative colitis, with increased CYP2J2 and reduced soluble epoxide hydrolase expression

Ordás, 2012, Ulcerative colitis, Lancet, 380, 1606, 10.1016/S0140-6736(12)60150-0 Asakura, 2009, Prevalence of ulcerative colitis and Crohn's disease in Japan, J. Gastroenterol., 44, 659, 10.1007/s00535-009-0057-3 Eaden, 2001, The risk of colorectal cancer in ulcerative colitis: a meta-analysis, Gut, 48, 526, 10.1136/gut.48.4.526 Jess, 2012, Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies, Clin. Gastroenterol. Hepatol., 10, 639, 10.1016/j.cgh.2012.01.010 Feagan, 2013, Vedolizumab as induction and maintenance therapy for ulcerative colitis, N. Engl. J. Med., 369, 699, 10.1056/NEJMoa1215734 Node, 1999, Anti-inflammatory properties of cytochrome P450 epoxygenase- derived eicosanoids, Science, 285, 1276, 10.1126/science.285.5431.1276 Campbell, 2010, Epoxyeicosatrienoic acids and endothelium-dependent responses, Pflugers Arch., 459, 881, 10.1007/s00424-010-0804-6 Enayetallah, 2004, Distribution of soluble epoxide hydrolase and of cytochrome P450 2C8, 2C9, and 2J2 in human tissues, J. Histochem. Cytochem., 52, 447, 10.1177/002215540405200403 Walker, 2016, Metabolism of anandamide by human cytochrome P450 2J2 in the reconstituted system and human intestinal microsomes, J. Pharmacol. Exp. Ther., 357, 537, 10.1124/jpet.116.232553 Klose, 1999, Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs, Biochem. Mol. Toxicol., 13, 289, 10.1002/(SICI)1099-0461(1999)13:6<289::AID-JBT1>3.0.CO;2-N Zhu, 2011, J. Chromatogr. B Anal. Technol. Biomed. Life Sci., 879, 2487, 10.1016/j.jchromb.2011.06.042 Zhang, 2012, Soluble epoxide hydrolase gene deficiency or inhibition attenuates chronic active inflammatory bowel disease in IL-10(-/-) mice, Dig. Dis. Sci., 57, 2580, 10.1007/s10620-012-2217-1 Zhang, 2013, Soluble epoxide hydrolase deficiency inhibits dextran sulfate sodium-induced colitis and carcinogenesis in mice, Anticancer Res., 33, 5261 Zhang, 2014, Stabilized epoxygenated fatty acids regulate inflammation, pain, angiogenesis and cancer, Prog. Lipid Res., 53, 108, 10.1016/j.plipres.2013.11.003 Fife, 2008, Inhibition of soluble epoxide hydrolase does not protect against endotoxin-mediated hepatic inflammation, J. Pharmacol. Exp. Ther., 327, 707, 10.1124/jpet.108.142398 Schroeder, 1987, Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis — a randomized study, N. Engl. J. Med., 317, 1625, 10.1056/NEJM198712243172603 Minuz, 2008, Altered release of cytochrome p450 metabolites of arachidonic acid in renovascular disease, Hypertension, 51, 1379, 10.1161/HYPERTENSIONAHA.107.105395 Sun, 2014, Soluble epoxide hydrolase-dependent regulation of myogenic response and blood pressure, Am. J. Physiol. Heart Circ. Physiol., 306, H1146, 10.1152/ajpheart.00920.2013 Deng, 2011, Endothelial CYP epoxygenase overexpression and soluble epoxide hydrolase disruption attenuate acute vascular inflammatory responses in mice, FASEB J., 25, 703, 10.1096/fj.10-171488 Li, 2014, Opposite effects of gene deficiency and pharmacological inhibition of soluble epoxide hydrolase on cardiac fibrosis, PLoS One, 9, e94092, 10.1371/journal.pone.0094092 Deng, 2010, Cytochrome P450 epoxygenases, soluble epoxide hydrolase, and the regulation of cardiovascular inflammation, J. Mol. Cell. Cardiol., 48, 331, 10.1016/j.yjmcc.2009.10.022 Wang, 2013, Soluble epoxide hydrolase inhibitors and cardiovascular diseases, Curr. Vasc. Pharmacol., 11, 105, 10.2174/157016113804547593 Bystrom, 2011, Endogenous epoxygenases are modulators of monocyte/macrophage activity, PLoS One, 6, e26591, 10.1371/journal.pone.0026591 Sanders, 2012, Soluble epoxide hydrolase expression in a porcine model of arteriovenous graft stenosis and anti-inflammatory effects of a soluble epoxide hydrolase inhibitor, Am. J. Physiol. Cell Physiol., 303, 278, 10.1152/ajpcell.00386.2011 Revermann, 2010, Soluble epoxide hydrolase deficiency attenuates neointima formation in the femoral cuff model of hyperlipidemic mice, Arterioscler. Thromb. Vasc. Biol., 30, 909, 10.1161/ATVBAHA.110.204099 Herse, 2012, Cytochrome P450 subfamily 2J polypeptide 2 expression and circulating epoxyeicosatrienoic metabolites in preeclampsia, Circulation, 126, 2990, 10.1161/CIRCULATIONAHA.112.127340 Oni-Orisan, 2016, Cytochrome P450-derived epoxyeicosatrienoic acids and coronary artery disease in humans: a targeted metabolomics study, J. Lipid Res., 57, 109, 10.1194/jlr.M061697 Schuck, 2013, Cytochrome P450-derived eicosanoids and vascular dysfunction in coronary artery disease patients, Atherosclerosis, 227, 442, 10.1016/j.atherosclerosis.2013.01.034 Li, 2015, CYP2J2 attenuates metabolic dysfunction in diabetic mice by reducing hepatic inflammation via the PPAR, Am. J. Physiol. Endocrinol. Metab., 380, 270, 10.1152/ajpendo.00118.2014 Bystrom, 2013, Inducible CYP2J2 and its product 11,12-EET promotes bacterial phagocytosis: a role for CYP2J2 deficiency in the pathogenesis of Crohn's disease?, PLoS One, 8, e75107, 10.1371/journal.pone.0075107